J. Goldman & Co’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-165,937
| Closed | -$3.92M | – | 556 |
|
|
2023
Q4 | $3.92M | Buy |
165,937
+26,988
| +19% | +$481K | 0.16% | 141 |
|
|
2023
Q3 | $2.07M | Buy |
+138,949
| New | +$1.84M | 0.07% | 201 |
|
|
2019
Q2 | – | Sell |
-153,298
| Closed | -$2.04M | – | 361 |
|
|
2019
Q1 | $2.04M | Buy |
+153,298
| New | +$1.63M | 0.11% | 164 |
|
|
2018
Q4 | – | Sell |
-41,912
| Closed | -$464K | – | 335 |
|
|
2018
Q3 | $464K | Sell |
41,912
-68,022
| -62% | -$845K | 0.03% | 226 |
|
|
2018
Q2 | $1.48M | Sell |
109,934
-345,666
| -76% | -$4.33M | 0.08% | 231 |
|
|
2018
Q1 | $5.92M | Sell |
455,600
-103,400
| -18% | -$1.28M | 0.25% | 109 |
|
|
2017
Q4 | $5.14M | Buy |
559,000
+26,000
| +5% | +$222K | 0.27% | 101 |
|
|
2017
Q3 | $4.3M | Sell |
533,000
-255,125
| -32% | -$1.73M | 0.22% | 126 |
|
|
2017
Q2 | $4.54M | Buy |
788,125
+62,125
| +9% | +$264K | 0.25% | 114 |
|
|
2017
Q1 | $3.12M | Buy |
726,000
+395,793
| +120% | +$1.14M | 0.15% | 173 |
|
|
2016
Q4 | $571K | Buy |
+330,207
| New | +$583K | 0.04% | 248 |
|
|
2016
Q2 | – | Sell |
-239,260
| Closed | -$323K | – | 424 |
|
|
2016
Q1 | $323K | Sell |
239,260
-117,000
| -33% | -$145K | 0.02% | 263 |
|
|
2015
Q4 | $602K | Sell |
356,260
-3,240
| -0.9% | -$5.28K | 0.06% | 200 |
|
|
2015
Q3 | $697K | Buy |
+359,500
| New | +$979K | 0.06% | 180 |
|
Other funds holding CBAY
J. Goldman & Co's CBAY Position: Q1 2024 in Review
J. Goldman & Co sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 165,937 shares — an estimated $3.92M sold.
J. Goldman & Co first reported a position in CBAY in Q3 2015 and held it in 14 quarters. The position peaked at $5.92M in Q1 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- J. Goldman & Co reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- J. Goldman & Co sold 165,937 Cymabay Therapeutics shares in Q1 2024, an estimated $3.92M.
- J. Goldman & Co first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 14 quarters.
- J. Goldman & Co's Cymabay Therapeutics position peaked at $5.92M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on J. Goldman & Co's 13F filing for Q1 2024, filed 15 May 2024.